Last reviewed · How we verify

Apidra (insulin glulisine)

Sanofi · FDA-approved active Small molecule

Insulin glulisine is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels.

Insulin glulisine is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameApidra (insulin glulisine)
SponsorSanofi
Drug classRapid-acting insulin analog
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Insulin glulisine is a recombinant human insulin analog with amino acid substitutions that accelerate its absorption and onset of action compared to regular human insulin. It binds to the insulin receptor, activating intracellular signaling that increases glucose transport into cells and promotes glycogen synthesis while inhibiting gluconeogenesis. This results in rapid lowering of postprandial and fasting blood glucose in patients with diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: